Here we report the phase 1 clinical trial testing triple therapy with dabrafenib, trametinib, and the anti-PD-L1 antibody durvalumab in patients with BRAFV600-mutant melanoma with a long-term follow-up (at least 3 years in all patients) to analyze the effect of these therapies on patients. The gene discussed is CD274; the disease is melanoma.